

Curriculum Vitae

April 13, 2015

JEFFREY GEOHAS, MD
Medical Director & Investigator

Evanston Premier Healthcare Research LLC
2500 Ridge Ave., Suite 109
Evanston, IL 60201
Phone: (847) 869-1191
Fax: (847) 869-6975
Email: jgeohas@evanstonpremier.com

EDUCATION

1985 – 1989 Undergraduate: Northwestern University, Evanston, Illinois, Neurobiology & Physiology
1989 - 1993 Medical: Northwestern University Medical School, Chicago, Illinois

TRAINING

1993 -1994 Internship: Internal Medicine, Evanston Northwestern Healthcare, Evanston, Illinois
Internship: Department of Medicine, Northwestern University, Medical School, Chicago, Illinois
1995 - 1996 Residency: Internal Medicine, Evanston Northwestern Healthcare-Department of Medicine, Northwestern University, Medical School, Evanston, Illinois
1994 Residency: Radiation Oncology, Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Washington University School of Medicine St. Louis, Missouri
1990 Fellowship: Baxter Fellowship

MEDICAL EXPERIENCE

2012 – Present President and Executive Medical Director of Evanston Premier Healthcare Research LLC
2010 – Present Instructor - Clinical Medicine, University of Chicago Pritzker School of Medicine, Evanston, Illinois
1997 – Present Internist, Private Practice, Evanston, Illinois
2002 – 2010 Medical Director, Radiant Research Chicago Center for Clinical Research, Chicago, Illinois (Formerly Protocare)
1999 – 2000 Investigator, Chicago Center for Clinical Research, North Shore Satellite, Evanston, Illinois
1997 – 2010 Clinical Investigator, Radiant Research Chicago Center for Clinical Research, Chicago, Illinois (Formerly Protocare)
1997 – 2009 Instructor – Clinical Medicine, Northwestern University Feinberg School of Medicine, Evanston, Illinois

CERTIFICATION AND LICENSURE

Licensure: State of Illinois Physician and Surgeon
License Number: 036-093330
2014-present AE Reporting (Ferring)
2014-present eCRF Completion Guidelines (Ferring)
2014-present GCP and Study Management (Ferring)
2014-present Inform GTM 5.5 PI Signature (Oracle)
2014-present Inform GTM 5.5 PI Date Entry and Signature (Oracle)
2013-present Good Clinical Practice for Investigational Site Staff 2.0 (Pfizer)

A. DeM
April 13, 2015

2013-present	Warner Chilcott General Training
2013-present	PR-05710 Clinical Study Drug Training
2013-present	eCRF Training for Site Users (Sanofi)
2013-present	Clinical Trial Portal – eTMF Training
2012-present	Audits and Inspections v.1 (Sanofi)
2012-present	Adverse Event Definitions and Reporting in Clinical Studies (Sanofi)
2012-present	Investigator Responsibilities v.1 (Sanofi)
2012-present	Drug Induced Liver Injury (DILI) v.1 (Sanofi)
2012-present	Inform v4.6 training
2012-present	CITI Good Clinical Practice Course, Basic Course
2012-present	CITI Health Information Privacy and Security (HIPS) for all Researchers, Basic Course
2012-present	Biomedical Research, Basic Course
2007-present	Inform v4.5 training

PUBLICATIONS

1. **Geohas, J.**, Roholt, N., Robinson, J. Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma. *J. Am. Acad. Dermatol* 1994; 30: 663-6.
2. Marymont, M., **Geohas, J.**, Tomita, T., et al. A pilot study of hyperfractional craniospinal radiotherapy in children with medulloblastoma submitted for publication in *J. Ped. Neurosurg.*
3. Singer GM, **Geohas, J.** The Effect of Chromium Picolinate and Biotin Supplementation on Glycemic Control in Poorly Controlled Patients with Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blinded, Randomized Trial *Diabetes Technol Ther.* 2006 Dec;8(6):636-43
4. Albarracin, C., Fuqua, B., **Geohas, J.**, et al. Combination of Chromium and Biotin Improves Coronary Risk Factors in Hypercholesterolemic Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blind Randomized Clinical Trial. *Journal of the CardioMetabolic Syndrome* Volume 2, Issue 2, pages 91–97, Spring 2007
5. Maki, K., Carson, M., Kerr Anderson WH, **Geohas, J.**, Reeves MS, Farmer MV, Turowski M, Miller M, Kaden VN, Dicklin MR, Rains TM. Lipid-altering effects of different formulations of hydroxypropylmethylcellulose . *J Clin Lipidol.* 2009 May-Jun;3(3):159-66. Epub 2009 May 5.
6. Maki, K., Mustad, V., Dicklin, M. and **Geohas, J.** Postprandial metabolism with 1,3-diacylglycerol oil versus equivalent intakes of long-chain and medium-chain triacylglycerol oils. *Nutrition* 25(6):627-33 (2009) PMID 19217260
7. Smith, S., Church, T., and **Geohas, J.** Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-I Study. American Diabetes Association 70th Scientific Meeting (2010). 70th Scientific Sessions, Abstract 1848-P

AWARDS AND PRIZES

1989 Phi Beta Kappa

RESEARCH ACTIVITIES

1994 -1995 Department of Radiation Oncology, Northwestern University Medical School
Chicago, Illinois

1994 Department of Dermatology, Northwestern University Medical School
Chicago, Illinois

1990 Baxter Fellow, Department of Geriatrics, Northwestern University Medical School, Chicago,
Illinois

1989 Department of Biochemistry, Northwestern University, Evanston, Illinois

CLINICAL RESEARCH EXPERIENCE

1. A Multicenter, Randomized, Double-Blind, Four Arm, Parallel Group Trial to Evaluate the Separate and Combined Effects of XXXX and XXXX on Serum Lipids Among Postmenopausal Women with Hypercholesterolemia. (304)
Co-Investigator: Jeffrey Geohas, M.D.
2. Multicenter, Double-Blind, Placebo-Controlled, Randomized Study on the Efficacy and Safety of XXXXXX During 3 Years Treatment in Patients with Postmenopausal Osteoporosis and Vertebral Fractures Using A Continuous Oral (2.5 mg daily) and an Intermittent Oral (20 mg every 2nd day for 24 days every 3 months) Dosing Regimen. (453)
Co-Investigator: Jeffrey Geohas, M.D.
3. A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of XXXXXX In Patients with Non-Insulin Dependant Diabetes Mellitus and Nephropathy (507)
Co-Investigator: Jeffrey Geohas, M.D.
4. A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of XXXXXX in the Prevention of Bone Loss in Early Postmenopausal Women (539)
Co-Investigator: Jeffrey Geohas, M.D.
5. A 2-Year Open Label, Multicenter, Active XXXXXX Comparison Study, to Evaluate the Effect of XXXXXX on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) (546)
Co-Investigator: Jeffrey Geohas, M.D.
6. A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of XXXXXX in the Prevention of Osteoporosis in Postmenopausal Women with Low Bone Mineral Density (644)
Co-Investigator: Jeffrey Geohas, M.D.
7. A Randomized, Double-Blind, Parallel Group Evaluation of XXXXXXXX Compared to XXXXXXXX and XXXXX/XXXXXXX Once Daily in Patients with Hypercholesterolemia. (650-Evanston)
Co-Investigator: Jeffrey Geohas, M.D.
8. An Investigation of the Pharmacokinetics of XXXXXX and the Effects of XXXXXX On Semen Characteristics When Administered Daily For 12 Months To Healthy Male Subjects (661)
Principal Investigator: Jeffrey Geohas, M.D.
9. An Investigation of the Metabolic Rate and Routes of Excretion of XXXXXX at Steady State in Healthy Male Subjects (661x1)
Principal Investigator: Jeffrey Geohas, M.D.
10. A Multi-Center, Double-Blind, Placebo Controlled Group Comparison Study to Investigate the Efficacy, Tolerance by Patients, and Safety of a Titrated Dose of XXXXXXXX in the Treatment of Hispanic Patients with Non-Insulin Dependent Diabetes Mellitus, Inadequately Controlled by Diet, With or Without XXXXXX Treatment (656)
Principal Investigator: Jeffrey Geohas, M.D.
11. A Twenty-Eight Week, Double-Blind and Observer-Blind to Lipid Values, Active-Controlled, Randomized, Parallel-Group Multi-center Study to Assess the Safety and Efficacy of XXXXXX Slow Release Form (80 mg) Administered Once Daily at Bedtime in Patients with Primary Hypercholesterolemia Compared to XXXXXX® 40 mg (685)
Co-Investigator: Jeffrey Geohas, M.D.
12. A Twenty-Eight Week, Open-Label, Multicenter, Extension Study to Prospectively Evaluate the Long-term Safety and Efficacy of XXXXXX 80 mg Slow Release (SR) Monotherapy in Patients with Primary Hypercholesterolemia (685x1)
Co-Investigator: Jeffrey Geohas, M.D.
13. A Comparison of XXXXXX and XXXXX in the Treatment of Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Agents. (694)
Principal Investigator: Jeffrey Geohas, M.D.
14. Safety and Efficacy of Fixed Combination XXXXXX/XXXXXX Products as First Line Therapy In Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise (735)
Co-Investigator: Jeffrey Geohas, M.D.
15. A Double-Blind Randomized Comparison of the Efficacy and Safety of 52 Weeks of XXXX Therapy Plus Diet in the Treatment of Obesity in Peri- and Post- Menopausal Women at Cardiovascular Risk. (744 Evanston)
Principal Investigator: Jeffrey Geohas, M.D.
16. A Multicenter, Open-Label, 12 Week Prospective Study to Evaluate the Effectiveness and Tolerability of XXXXXX in Hypertensive Patients Participating in the XXXXXXXX Who Have Not Adequately Responded to Angiotensin-Converting Enzyme Inhibitor Monotherapy. (741)
Co-Investigator: Jeffrey Geohas, M.D.
17. A Long Term Open Label Extension Trial of a Single Dose of XXXXXX in Postmenopausal Women (755)
Co-Investigator: Jeffrey Geohas, M.D.
18. A Long-Term Study of the Safety and Effectiveness of XXXXXX Gel for Hormonal Replacement in Hypogonadal Men (773)
Principal Investigator: Jeffrey Geohas, M.D.

19. Triple-Blind, Randomized, Parallel, Efficacy Study of XXXXX vs. XXXXX in Patients with Mild to Moderate Essential Hypertension. (780)
Principal Investigator: Jeffrey Geohas, M.D.
20. A Multi-Center, Double-Blind, Randomized, Single-Dose, Placebo-Controlled Study to Investigate the Efficacy and Safety of XXXXX and XXXXXX in Preventing Meal-Induced Heartburn Symptoms Following a Provocative Meal (782)
Principal Investigator: Jeffrey Geohas, M.D.
21. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Efficacy Trial of Combination Therapy of XXXXXX XXXXXX Plus XXXXXX (Once Daily Dosing) in Adult Patients with Hypertension (932)
Principal Investigator: Jeffrey Geohas, M.D.
22. A Multicenter, Randomized, Parallel Group Study to Evaluate the Effect of Dosing Time on Efficacy and Safety of XXXX in Patients with Primary Hypercholesterolemia. (939)
Co-Investigator: Jeffrey Geohas, M.D.
23. A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Effects of XXXXXX and Continuous Combined Conjugated XXXXXX Plus XXXXXX XXXXXX on Intimal-Medial Thickness of the Carotid Arteries and Bone Mineral Density of the Lumbar Vertebrae and Proximal Femur in Postmenopausal Women (966)
Principal Investigator: Jeffrey Geohas, M.D.
24. A Phase I Single Center Study in Normal Volunteers for the Purpose of Demonstrating Instrument Setting Procedures on Commercially Available Ultrasound Equipment to be Used with XXXXXX XXXXXX for Injection when Administered Intravenously. (968)
Principal Investigator: Jeffrey Geohas, M.D.
25. A Multicenter, Randomized, Double-Blind, XXXXXX and Placebo Controlled Trial of the Anti-hypertensive Efficacy and Safety of XXXXX in Black Subjects with Mild to Moderate Hypertension. (974)
Principal Investigator: Jeffrey Geohas, M.D.
26. A 52-Week, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of XXX Treatment in Obese Patients with Type 2 Diabetes Inadequately Controlled with Insulin. (982 Evanston)
Principal Investigator: Jeffrey Geohas, M.D.
27. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of XXXXXX XXXXXX in Patients with Essential Hypertension (991)
Principal Investigator: Jeffrey Geohas, M.D.
28. Phase IV Post-Marketing Pharmacovigilance of XXXXXX Treated Plasma. (1011)
Principal Investigator: Jeffrey Geohas, M.D.
29. A Single-Dose Cross-Over Study of XXXXX in the Reversal of Broncho-Constriction in Asthmatic Adults (1021)
Principal Investigator: Jeffrey Geohas, M.D.
30. A Multicenter, Six-Week, Randomized, Open-Label, Parallel Arm Study Comparing the Efficacy of XXX XXXXX to XXXXX in Hypercholesterolemic Patients (1061)
Co-Investigator: Jeffrey Geohas, M.D.
31. A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of XXXX Administered XXXXXX in Patients with Type 2 Diabetes who Have Inadequate Glycemic Control with Diet and Exercise. (1063)
Principal Investigator: Jeffrey Geohas, M. D.
32. A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of XXXXXX Oral Dose Form (Biphasic Tablet) Administered Either Once or Twice a Day in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet And Exercise (1063 Evanston)
Principal Investigator: Jeffrey Geohas, M. D.
33. Efficacy and Safety of Inhaled Compared with Subcutaneous XXXXXX Therapy in Subjects with Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial (1090)
Co-Investigator: Jeffrey Geohas, M.D.
34. Efficacy and Safety of Inhaled XXXXXX Therapy in Subjects with Type 2 Diabetes Mellitus Not Well Controlled with Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial (1093)
Co-Investigator: Jeffrey Geohas, M.D.
35. A Randomized, Placebo-Controlled, Parallel Group (with Subject Option for Treatment Switch), Double-Blind Study (with Open Label Treatment Extension) to Evaluate the Efficacy and Safety of XXXXXX® (XXXXXX XXXXXX) in Black Americans with Erectile Dysfunction (1096)
Principal Investigator: Jeffrey Geohas, M.D.
36. A 16-Week, Double-Blind and Observer-Blind-to-Lipid-Value, Randomized, Parallel-Group, Multi-center, Active-Controlled Study to Assess the Efficacy and Safety of XXXX Compared to XXXXX Both Administered Every Evening at Bedtime in Patients with Mixed Dyslipidemia. (1100)
Principal Investigator: Jeffrey Geohas, M. D.
37. Phase II Double-Blind, Placebo-Controlled Trial of the Safety, Toleration and Efficacy of XXXXXX and XXXXXX 60 mg/d for the Prevention of Bone Loss in Postmenopausal Women (1199)

- Co-Investigator: Jeffrey Geohas, M.
38. A Comparison of the Effect of Two Doses of XXX with XXXXX ® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma (1223)
Principal Investigator: Jeffrey Geohas, M. D.
39. XXXXXX vs. XXXXXX Symptoms Relief Study (1233)
Principal Investigator: Jeffrey Geohas, M. D.
40. A Randomized, Double-Blind Controlled Trial Analyzing the Lipid-Altering Effects of XXXXXX and XXXXXX in Postmenopausal Women (1251 Evanston)
Principal Investigator: Jeffrey Geohas, M. D.
41. A Double-Blind, Randomized, Parallel-Group, Multiple-Dose Study to Compare the Efficacy of XXXXXX/XXXXX Combination, XXXXXX 10mg, Antacid, and Placebo in Patients With Frequent Heartburn (No.2). (1440 Evanston)
Principal Investigator: Jeffrey Geohas, M. D.
42. A Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Subcutaneously Administered XXXXXX in Obese Subjects (1534)
Co-Investigator: Jeffrey Geohas, M.D.
43. A Multicenter, Age-Stratified, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Range Finding Study to Evaluate the Safety and Efficacy of a Fixed Dose Regimen of XXXXXX 2mg and XXXXXX 1mg in Men with Lower Urinary Tract Symptoms (1537)
Principal Investigator: Jeffrey Geohas, M. D.
44. A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Four Doses of XXXXX in Obese Patients (1600)
Principal Investigator: Jeffrey Geohas, M.D.
45. A Multicenter, Double-Blind, Randomized, Single-Dose, Placebo-Controlled Study to Investigate the Efficacy and Safety of 20.6 mg and 10.3 mg XXXXXX XXXXXX in Treating Heartburn Symptoms Following a Provocative Meal (1602)
Co-Investigator: Jeffrey Geohas, M.D.
46. A Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of XXXXXX vs. Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy (1710)
Principal Investigator: Jeffrey Geohas, M.D.
47. An Open-Label, Randomized, Parallel-Group Study to Compare XXXXXX Plus XXXXXX vs. XXXXXX Plus XXXXXX in the Treatment of Type 2 Diabetes (1737)
Co-Investigator: Jeffrey Geohas, M.D.
48. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Evaluation of Oral XXXXXX Tablets (2.5mg, 5mg or 7.5mg) as a Monotherapy for 26 Weeks in Subjects with Type 2 Diabetes Mellitus with an Optional 52 Week Open-Label Extension (1762)
Principal Investigator: Jeffrey Geohas, M.D.
49. A Randomized, Double-Blind, Placebo Controlled Trial of XXXXXX Alone and in Combination with XXXXXX in Patients with Primary Hypercholesterolemia (2267 Evanston)
Principal Investigator: Jeffrey Geohas, M.D.
50. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 6-Week Evaluation of the XXXXXX 0.4 mg and XXXXXX 10 mg in Post-Menopausal Women with Hyperlipidemia and a 46-Week Evaluation in which XXXXXX 0.4 mg and XXXXXX 0.8mg are Compared to XXXXXX 201 mg for Long-Term Lipid-Lowering and Bone Mineral Density Effects (2281)
Co-Investigator: Jeffrey Geohas, M.D.
51. To Determine the Effect of Increasing Doses of XXXXXX XXXXXX Derived XXXXXX on the Plasma Lipid Levels of Hypercholesterolemic Patients (2292 Evanston)
Principal Investigator: Jeffrey Geohas, M.D.
52. A Randomized, Double-Blinded Clinical Trial to Evaluate the Influence of XXXXXX on Serum Lipids in Men and Women with Hypercholesterolemia (2302)
Principal Investigator: Jeffrey Geohas, M.D.
53. Randomized, Double-Blind, Multicenter Phase III Trial of the Comparative Immunogenicity, Safety and Tolerability of Two XXXXXX (2370)
Principal Investigator: Jeffrey Geohas, M.D.
54. A Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 45 mg of XXXXXX™ (XXXXXX) Compared to a Combination of Insulin and 30 mg of XXXXXX™ (XXXXXX) in the Treatment of Patients with Type 2 (Non-Insulin Dependent) Diabetes Mellitus (2376)
Principal Investigator: Jeffrey Geohas, M.D.
55. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled XXXXXX 10 mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged > 65 Years. (2428)
Principal Investigator: Jeffrey Geohas, M.D.
56. A Six Week Trial XXXXXX XXXXXX 1 mg Twice Daily as Empirical Therapy in Female Subjects with Symptoms of Diarrhea Predominant Irritable Bowel Syndrome (2431)

Principal Investigator: Jeffrey Geohas, M.D.

57. Long Term Safety of Inhaled XXXXXX: Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials (2435)
Co-Investigator: Jeffrey Geohas, M.D.
58. A Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Clinical Trial to Assess the Effect of Three Months Repeated Daily Oral 1200 mg Doses of XXXXXX in Combination with Oral XXXXXX, on Glycemic Control and Lipid Profiles in Obese Patients with Type 2 Diabetes (2529)
Principal Investigator: Jeffrey Geohas, M.D.
59. A Phase III Double-Blind Efficacy and Safety Study of XXXXXX (10 mg) in Addition to XXXXXX Compared to Placebo in Subjects with Primary Hypercholesterolemia (2532)
Principal Investigator: Jeffrey Geohas, M.D.
60. A Study of Blood Cholesterol Levels in Subjects Consuming a Cholesterol Lowering Diet Including XXXXXX® (2538)
Principal Investigator: Jeffrey Geohas, M.D.
61. Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety and Pharmacokinetic Profile of AT-1015 in Patients with Peripheral Arterial Disease (2551)
Co-Investigator: Jeffrey Geohas, M.D.
62. Evaluation of XXXXXX/XXXXXX -Treated Plasma, Isoagglutinin Depleted, In Normal Healthy Volunteers (2558)
Principal Investigator: Jeffrey Geohas, M.D.
63. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of XXXXXX 12mg/d and Placebo in Females with Constipation-Predominant Irritable Bowel Syndrome (C-IBS) (2595)
Principal Investigator: Jeffrey Geohas, M.D.
64. A Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel Group, Multicenter Study Assessing the Safety and Biological Activity of Oral XXXXXX XXXXXX on Biochemical Markers of Bone Remodeling (2625)
Principal Investigator: Jeffrey Geohas, M.D.
65. A Randomized, Single-Dose, Double-Blind, Parallel Study Comparing XXXXXX 20 mg, XXXXXX 10 mg and Placebo in Preventing Heartburn When Administered Immediately Prior to a Provocative Breakfast Meal (2666)
Principal Investigator: Jeffrey Geohas, M.D.
66. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Flexible Dose Study to Evaluate the Efficacy and Safety of XXXXXX™ in Males with Erectile Dysfunction and Arterial Hypertension Who Are Taking Multiple Antihypertensive Treatments (2770)
Principal Investigator: Jeffrey Geohas, M.D.
67. A Phase III Study of the Efficacy and Safety of XXXXXX in Subjects with Symptomatic Benign Prostatic Hyperplasia (2777)
Principal Investigator: Jeffrey Geohas, M.D.
68. A Double-Blind Placebo-Controlled Study of XXXXXX in Patients with Intermittent Claudication due to Peripheral Arterial Disease (2788)
Principal Investigator: Jeffrey Geohas, M.D.
69. A Randomized, Double-Blind, Placebo Controlled Trial of Once Per Day vs. Split Dosing of XXXXXX XXXXXX in Patients with Hypercholesterolemia (2794)
Co-Investigator: Jeffrey Geohas, M.D.
70. A Randomized, Double-Blind Study to Determine the Efficacy of XX in the Treatment of African American Patients with Asthma (2796)
Principal Investigator: Jeffrey Geohas, M.D.
71. A Double-Blind Comparison of 80 and 160 mg Doses of XXXXXX with Placebo in Hypercholesterolemic Subjects (2906)
Principal Investigator: Jeffrey Geohas, M.D.
72. XXXXXX Cardiovascular Treatment Assessment vs. XXXXXX (2943)
Co-Investigator: Jeffrey Geohas, M.D.
73. A 12 Week Double Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of XXXXXX in Patients with Low HDL-C and Either Normal or Elevated Triglycerides (2944)
Co-Investigator: Jeffrey Geohas, M.D.
74. A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of XXXXX for the Treatment of Male Erectile Dysfunction in an At-Home Setting (3601)
Principal Investigator: Jeffrey Geohas, M.D.
75. An Open-Label Continuation Trial of XXXXXX n Male ED Patients Who Previously Participated in XXXXXX (3601x1)
Principal Investigator: Jeffrey Geohas, M.D.
76. A 16-Week, Double-Blind, Multicenter Study to Evaluate the Effect of XXXXX in Combination With XXXXX on Lipids in Patients With Type IIa and IIb Dyslipidemia (3575)
Principal Investigator: Jeffrey Geohas, M.D.

77. A Randomized, Double Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of XXXXX in Adult Subjects With Insomnia (3572)
Principal Investigator: Jeffrey Geohas, M.D.
78. A Phase III, Vehicle-Controlled Study of Topical XXXXX Gel Applied 2 Times per Week for 1 Week for Each Recurrence of Herpes Genitalis over 12 Months. (3685)
Principal Investigator: Jeffrey Geohas, M.D.
79. A Randomized, Double-Blind, Placebo-Controlled Parallel, Two-Week Efficacy and Safety Study of XXXXX in Elderly Subjects with Primary Insomnia (3703)
Principal Investigator: Jeffrey Geohas, M.D.
80. A Dose-Ranging Study of XXXXX In Patients With Primary Hypercholesterolemia (3518)
Principal Investigator: Jeffrey G. Geohas, M.D.
81. Randomized, Double-Blind, Placebo-Controlled, 14-Day, Dose-Ranging Study of XXXXX in the Treatment of Subjects with Poor Sleep Quality (3769)
Principal Investigator: Jeffrey G. Geohas, M.D.
82. An Open Label, Multi-center, Flexible Dose Escalation Study to Measure Treatment Responsiveness of Quality of Life Instruments in Men with Erectile Dysfunction Treated with XXXXX (3700)
Principal Investigator: Jeffrey G. Geohas, M.D.
83. A Double-Blind Placebo-Controlled, Parallel-Group Safety And Efficacy Study Evaluating Three Dose Regimens Of XXXXX, A Selective Alpha-Adrenergic Antagonist, In The Treatment of Benign Prostatic Hyperplasia (3750)
Principal Investigator: Jeffrey G. Geohas, M.D.
84. Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study (3783)
Principal Investigator: Jeffrey G. Geohas, M.D.
85. Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release XXXXX and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip (3881)
Principal Investigator: Jeffrey G. Geohas, M.D.
86. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXXXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease (3868)
Principal Investigator: Jeffrey G. Geohas, M.D.
87. Phase III, Vehicle Controlled Study of Topical XXXXX Gel Applied 2 Times per Week for 3 Weeks for Each Recurrence of Herpes Genitalis over 12 Months (3777)
Principal Investigator: Jeffrey G. Geohas, M.D.
88. A Randomized, Double-Blind, Multi-Center Study to Assess the Safety of Long-Term Administration of Two Dose Levels of XXXXX in Patients with Primary Insomnia (3930)
Principal Investigator: Jeffrey G. Geohas, M.D.
89. XXXXX in Type 2 Diabetic Subjects: A Fifty-Two Week Double-Blind, Parallel, Active-Controlled Study (Followed by a Fifty-Two Week Open-Labeled Extension) to Investigate Safety and Efficacy (4120)
Principal Investigator: Jeffrey G. Geohas, M.D.
90. Glycemic Response of Foodstuffs Using a Meal Tolerance Test (3922)
Sub-Investigator: Jeffrey G. Geohas, M.D.
91. A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing the Percentage of Patients Achieving Low Density Lipoprotein Cholesterol Target With XXXX Starting Doses of XXXXX (4168)
Principal Investigator: Jeffrey G. Geohas, M.D.
92. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effects of XXXXX on Blood Pressure in Men and Women with Mild to Moderate Hypertension (4087)
Principal Investigator: Jeffrey G. Geohas, M.D.
93. XXXXX in Combination with XXXXX® Versus XXXXX plus XXXXX in Type 2 Diabetes: A Six Month, Double-Blind (with Open-Labeled XXXXX), Multicenter, Randomized, Parallel Study of Efficacy and Safety (4322)
Principal Investigator: Jeffrey G. Geohas, M.D.
94. XXXXX in Type 2 Hypertriglyceridemic Diabetic Subjects: A Twenty-six Week, Double-Blind, Multicenter, Randomized, Parallel, Active-Controlled (XXXXX plus XXXXX) Study to Investigate Safety and Efficacy (4323)
Principal Investigator: Jeffrey G. Geohas, M.D.
95. A Randomized, Double-Blind, Multi-Center, Fixed-Dose, Cross-Over Study To Investigate The Efficacy And Safety Of XXXXX Given On Demand In Comparison To XXXXX Given On Demand In Males With Erectile Dysfunction And A Diagnosis Of Diabetes Mellitus And/Or Hypertension And/Or Hyperlipidemia (3521)
Principal Investigator: Jeffrey G. Geohas, M.D.

96. A Phase I/II Randomized, Double-Blind, Active-Controlled, Dose Escalation Study Of The Safety, Tolerance, Pharmacokinetics, And Antiviral Activity Of XXXXXX In Antiretroviral-Naïve Patients Who Are Chronically Infected With HIV-1 (4319)
Principal Investigator: Jeffrey G. Geohas, M.D.
97. Efficacy and Safety of XXXXXX Compared with XXXXXX Therapy in Adult Subjects with Type 1 Diabetes Mellitus: A Two-year, Outpatient, Open-label, Parallel-Group Comparative Trial. (4275)
Principal Investigator: Jeffrey G. Geohas, M.D.
98. An Open-Label, Parallel Design, Twelve Month Phase 3 Trial of the Safety and Efficacy of XXXXXX in Male Patients with Erectile Dysfunction (4453)
Principal Investigator: Jeffrey G. Geohas, M.D.
99. A Randomized, Double-Blind, Placebo-Controlled Study Of XXXXXX Sustained Release Formulation Prototypes In Subjects With Hypercholesterolemia (4395)
Principal Investigator: Jeffrey G. Geohas, M.D.
100. A Randomized, Placebo-Controlled Clinical Trial to Evaluate the Effects of XXXXXX Consumption on Blood Pressure in Overweight Men and Women with Mild Hypertension (3634)
Principal Investigator: Jeffrey G. Geohas, M.D.
101. A Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Escalation Study to Evaluate Self-Esteem and Overall Relationship in Men with Erectile Dysfunction Treated with XXXXXX in the United States (3792)
Principal Investigator: Jeffrey G. Geohas, M.D.
102. A Randomized, Open Label, Multicenter, Crossover Trial of XXXXXX vs XXXXXX Utilization on NCEP ATP III Goal Achievement in Persons with Moderate Risk for Coronary Heart Disease: The LAUNCH Study (3967)
Principal Investigator: Jeffrey G. Geohas, M.D.
103. Efficacy and Safety of XXXXXX Compared with Subcutaneous Human Insulin Therapy in Adult Subjects with Type 2 Diabetes Mellitus: A two-year, Outpatient, Open-Label, Parallel Group Comparative Trial (4473)
Principal Investigator: Jeffrey G. Geohas, M.D.
104. Phase II Dose Ranging Study of XXXXXX in Patients with Chronic Pain Due to Osteoarthritis (4381)
Principal Investigator: Jeffrey G. Geohas, M.D.
105. A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effects of XXXXXX on Blood Pressure in Subjects with Untreated or Sub-optimally Treated Blood Pressure Elevation (4482)
Principal Investigator: Jeffrey G. Geohas, M.D.
106. A Double-Blind, Randomized, Parallel-Group, Phase III Trial Comparing the Safety and Efficacy of XXXXXX and XXXXXX and Placebo in Adult Patients with Hypercholesterolemia (4474)
Principal Investigator: Jeffrey G. Geohas, M.D.
107. An Open-Label, Randomized, Parallel-Group, Multicenter, Phase III Study Comparing the Safety and Efficacy of XXXXXX and XXXXXX In Adult Patients with Hypercholesterolemia (4475)
Principal Investigator: Jeffrey G. Geohas, M.D.
108. A Multicenter, Open-Label Extension, Flexible Dose Escalation Study to Evaluate Self-Esteem and Overall Relationships in Men with Erectile Dysfunction Treated with XXXXXX in the United States (4326)
Principal Investigator: Jeffrey G. Geohas, M.D.
109. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of XXXXXX Combination Tablet in Patients with Primary Hypercholesterolemia (4535)
Principal Investigator: Jeffrey G. Geohas, M.D.
110. Randomized, Double Blind, Three Way Crossover Comparison of Glucose and Insulin Responses During a Glucose Tolerance Test in Subjects with Type 2 Diabetes Consuming Disease-Specific Versus Standard Nutritional Formulas (4568)
Principal Investigator: Jeffrey G. Geohas, MD
111. Comparison of the Efficacy and Safety of Two Oral Doses of XXXXXX or XXXXXX, Versus Placebo, as an Aid to Maintenance of Smoking Cessation – A Multiple Country, Randomized, Double-Blind, Five Arm, Placebo-Controlled, Parallel-Group, Fixed Dose, Two-Year, Multi-Center, Phase III Trial; One-Year Treatment, One-Year Follow-Up" (4416)
Principal Investigator: Jeffrey G. Geohas, MD
112. The Efficacy and Safety of the XXXXXX Transdermal System for Smoking Cessation (4493)
Principal Investigator: Jeffrey G. Geohas, MD
113. Effects of Induced-Viscosity Formulas on Safety in Healthy Adult Male Subjects (4285)
Principal Investigator: Jeffrey G. Geohas, MD

114. A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing XXXXX and XXXXX in Patients with Mild-to-Moderate Hypertension using Ambulatory Blood Pressure Monitoring (4598)
Principal Investigator: Jeffrey G. Geohas, MD
115. A Double-Blind, Randomized, Placebo-Controlled, Clinical Study to Evaluate the Effect of XXXXX on Body Fat Mass in Overweight or Obese Men and Women (4558)
Principal Investigator: Jeffrey G. Geohas, MD
116. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus XXXXX Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
Principal Investigator: Jeffrey G. Geohas, MD
117. The Efficacy, Onset of Effect, and Safety of XXXXX Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score (ALF-ACUTE) (4478)
Principal Investigator: Jeffrey G. Geohas, MD
118. An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Men of Various Populations with Erectile Dysfunction.(202373)
Principal Investigator: Jeffrey G. Geohas, MD
119. The TROPIC Study: The Dose Response of XXXX/XXXX on Peak Walking Time (PWT) in Patients with Intermittent Claudication-a Matrix Design (202525)
Principal Investigator: Jeffrey G. Geohas, MD
120. A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of XXXX Combination Tablet Versus XXXX in Patients with Hypercholesterolemia (202451)
Principal Investigator: Jeffrey G. Geohas, MD
121. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of XXXX in the Treatment of Rapid Ejaculation (201499)
Principal Investigator: Jeffrey G. Geohas, MD
122. A Double-Blind, Randomized, Parallel-group Pilot Study of Oral XXXX versus placebo in the Prevention of Highly Active Antiretroviral Therapy (HAART)-related Nausea and Vomiting (202847)
Principal Investigator: Jeffrey G. Geohas, MD
123. A Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Effects of a Weight Loss Supplement in Healthy Overweight/Moderately Obese Volunteers. (202875)
Principal Investigator: Jeffrey G. Geohas, MD
124. A Twelve Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy of XXXX of Comparison to XXXX® For Smoking Cessation. (203034)
Principal Investigator: Jeffrey G. Geohas, MD
125. A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus. (202709)
Principal Investigator: Jeffrey G. Geohas, MD
126. A 12-Month, Open-Label, Flexible-Dosage (xxx to xxx mg/day) Study of the Safety and Efficacy of XXXX in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. (203260)
Principal Investigator: Jeffrey G. Geohas, MD
127. A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 3 Bridging Trial of the Efficacy and Safety of XXXXX in Male Subjects with Erectile Dysfunction (203292)
Principal Investigator: Jeffrey G. Geohas, MD
128. An Open-Label, Long-Term, Phase 3 Trial of the Safety and Efficacy of XXXXX in Male Subjects with Erectile Dysfunction. (203440)
Principal Investigator: Jeffrey G. Geohas, MD
129. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of XXXX, With and Without Food, Versus a Matching Placebo, Combined With a Low Saturated-Fat Diet in Subjects with Hypertriglyceridemia and Metabolic Syndrome (203187)
Principal Investigator: Jeffrey G. Geohas, MD
130. A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Multicenter Study to Evaluate the Improvement in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of XXXX in Patients With Type 2 Diabetes Mellitus (203369)
Principal Investigator: Jeffrey G. Geohas, MD
131. A Phase I/II Study to Evaluate the Safety, Tolerance and Immunogenicity of XXXX Influenza Vaccine versus XXXX Influenza Vaccine in Healthy Adults 50-64 Years of Age and Elderly Adults ≥ 65 Years of Age (203538).
Principal Investigator: Jeffrey G. Geohas, MD

132. A 24-Week, Randomized, Double-Blind, Multi-Centre, Active-Controlled (XXXX) Study to Evaluate the Efficacy, Safety and Tolerability of XXXX Therapy when Administered to Patients with Type 2 Diabetes (203360).
Principal Investigator: Jeffrey G. Geohas, MD
133. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of an Immediate Release Formulation of XXXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties (204069).
Principal Investigator: Jeffrey G. Geohas, MD
134. A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy and Safety Extension Study of XXXX in the Treatment of Adult Outpatients With Primary Insomnia. (204888)
Principal Investigator: Jeffrey G. Geohas, M.D.
135. A Clinical Study to Identify Normal Healthy Adults Without *in vitro* Serum Bactericidal Activity (SBA) Against *N. meningitidis* and to Obtain Blood Donations From Selected SBA Negative Donors. (205138)
Principal Investigator: Jeffrey G. Geohas, M.D.
136. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment with XXXX in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data. (203428)
Principal Investigator: Jeffrey G. Geohas, M.D.
137. A Double-Blind, Multi-center, Active-Controlled (XXXX) Long-Term Extension Study to Evaluate the Safety and Tolerability of XXXX in Patients with Type 2 Diabetes Mellitus. (204980)
Principal Investigator: Jeffrey G. Geohas, M.D.
138. Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of XXXX Vs. XXXX as Vaccines for Japanese Encephalitis in Healthy Volunteers. (205223)
Principal Investigator: Jeffrey G. Geohas, M.D.
139. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing With XXXX in the Treatment of Premature Ejaculation. (204573)
Principal Investigator: Jeffrey G. Geohas, M.D.
140. A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and It's Safety and Tolerability in Obese Subjects. (205189)
Principal Investigator: Jeffrey G. Geohas, M.D.
141. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined XXXX and Simvastatin Therapy in Hypertriglyceridemic Subjects. (205358)
Principal Investigator: Jeffrey G. Geohas, MD
142. An Open-Label Pilot Study to Assess the Safety and Immune Effects of Diatar Supplementation with DIAM-H-04-2. (205151)
Principal Investigator: Jeffrey G. Geohas, MD
143. A Pilot Clinical Trial to Assess the Safety and Tolerability of XXXX in Healthy Adults. (204506)
Principal Investigator: Jeffrey G. Geohas, MD
144. A 12-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel group Study to Assess the Safty and Efficacy of XXXX in Obese Patients. (205606)
Principle Investigator: Jeffrey G. Geohas, MD
145. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of XXXX Influenza Vaccine in Healthy Adults 18 – 49 Years of Age. (205395)
PI: Jeffrey G. Geohas, MD
146. A Randomized, Double-Blind, Controlled, Parallel Study to Test the Efficacy of XXXX for Enhancing Loss of Fat Mass in Overweight and Obese Men and Women Undergoing a Mild Energy Restriction. (204194)
PI: Jeffrey G. Geohas, MD
147. A Multicenter, Placebo Controlled, Randomized, Double-Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical XXXX Application of XXXX Cream with an Open Label Conventional Therapy Treatmetn Arm, and a Blinded Evaluator, for the Episodic Treatment of Recurrent Herpes Labialis. (204467)
PI: Jeffrey G. Geohas, MD
148. Extension Study of Protocol 137OB-201E to Examine the Long-Term Effect of XXXX on Body Weight and It's Safety and Tolerability in Obese Subject. (205875)
PI: Jeffrey G. Geohas, MD
149. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of XXXX in Subjects With Primary Hypercholesterolemia. (205848)
PI: Jeffrey G. Geohas, MD
150. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX. (205211)
PI: Jeffrey G. Geohas, MD

151. A Non-Inferiority Comparison of XXXX Influenza Virus Vaccine to a US Licensed Inactivated Split-Virion Vaccine (XXXX) in Adults \geq 50 Years Old Living in the Community. (205442)
PI: Jeffrey G. Geohas, MD
152. A Multicenter, Randomized, Double Blind, Phase III Study of the Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (XXXX and XXXX) (205604)
PI: Jeffrey G. Geohas, MD
153. A Long-Term, Post Treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies. (205867)
PI: Jeffrey G. Geohas, MD
154. A 6-week, multicenter, randomized, double – blind, parallel – group treatment regimen study to evaluate the efficacy of initial high dose XXXX monotherapy (160mg) or combination therapy (XXXX + XXXX, 160/12.5mg) to conventional low – dose XXXX monotherapy (80mg) in managing patients with hypertension. (206140)
PI: Jeffrey G. Geohas, MD
155. An Open – Label Extension of a Randomized, Double – Blind, Placebo – Controlled Study to Assess the Efficacy and Safety of Combined XXXX and XXXX Therapy in Hypertriglyceridemic Subjects. (206188)
PI: Jeffrey G. Geohas, MD
156. An Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX. (205761)
PI: Jeffrey G. Geohas, MD
157. Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of XXXX (XXXX) vs. XXXX as Vaccines for Japanese Encephalitis in Healthy Subjects. (203897)
PI: Jeffrey G. Geohas, MD
158. Phase I/II, Double-Blind, Randomized Study to Assess the Safety and Immunogenicity of XXXX Supplied by Two Different Manufacturers in Healthy Adults. (206435)
PI: Jeffrey G. Geohas, MD
159. An Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX. (205761)
PI: Jeffrey G. Geohas, MD
160. A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX. (206511)
PI: Jeffrey G. Geohas, MD
161. A Phase II Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection with Enterotoxigenic Escherichia coli Occurring after Transcutaneous Immunization in a Field Setting. (207034)
PI: Jeffrey G. Geohas, MD
162. A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of XXXXXXX in Obese Patients. (207149)
PI: Jeffrey G. Geohas, MD
163. Immunogenicity and Safety of The Split, Inactivated, Trivalent XXXXXXXX Administered by Intradermal Route in Comparison with XXXXXXXX with Standard XXX in Ambulatory Elderly Subjects. (206660)
PI: Jeffrey Geohas, MD
164. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of XXXX Influenza Vaccine in Healthy Adults 18-49 Years of Age (Season #2). (205395)
PI: Jeffrey G. Geohas, MD
165. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of XXXXX on Body Weight in Obese Subjects. (206917)
166. A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study To Evaluate The Safety, Tolerability, and Effect On Body Weight of XXXXXXX Human Leptin Administered In Conjunction with XXXXXXX In Overweight And Obese. (207166)
PI: Jeffrey G. Geohas, MD
167. A randomized, double-blind, active-controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of XXXXXXX versus XXXXXXX for treatment of recurrent herpes simplex labialis. (206690)
PI: Jeffrey G. Geohas, MD
168. A Multi-Center, Double-Blind, Parallel-Group, Randomized Study Comparing the Efficacy and Safety of XXXXXXX versus XXXXXXX as Add-On Therapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on the Maximum Effective Dose of XXXXXXX and Combination Therapy. (207215)
PI: Jeffrey G. Geohas, MD

169. Multicenter, Randomized, Double-Blind Titration Study to Evaluate and Compare the Efficacy and Safety of XXXX Added On to XXXXX versus Up Titration to XXXXXX in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease Not Adequately Controlled on XXXXX. (207090)
PI: Jeffrey G. Geohas, MD
170. Multicenter, Randomized, Double-Blind Titration Study to Evaluate and Compare the Efficacy and Safety of XXXX Added On to XXXXX versus Up Titration to XXXX in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease No Adequately Controlled on XXXX. (207089)
PI: Jeffrey G. Geohas, MD
171. A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of XXXXX on Symptomatic Peripheral Arterial Disease. (207416)
PI: Jeffrey G. Geohas, MD
172. A Phase III Clinical Trial to Evaluate the Safety and Tolerability of XXXXX in Subjects 50 to 59 Years of Age. (207455)
PI: Jeffrey G. Geohas, MD
173. A Study Evaluating the Co-Administration of XXXXXX in combination with Aspirin to Minimize Flush with Placebo Control and Double Blinding. (207302)
PI: Jeffrey G. Geohas, MD
174. Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed XXXXXX in person \geq 65 Years of Age. (207178)
PI: Jeffrey G. Geohas, MD
175. Phase I/II Randomized Study to Evaluate the Safety and Immunogenicity of Transcutaneous Trivalent XXXXXXXXXXXX with Different Doses of Heat-Labile Enterotoxin of Escherichia coli in Healthy Adults (207243)
PI: Jeffrey G. Geohas, MD
176. A Phase II, 28-day Partially Blinded, Multicenter, Randomized, Parallel-group Study to Evaluate 200 and 300 ug Daily XXXXXXXXXXXX compared to Daily Forteo on Bone Turnover Makers, Pharmacokinetics, and Safety in Postmenopausal Women (206846)
PI: Jeffrey G. Geohas, MD
177. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of The Combination of XXXXXX And XXXXXX 20 MG VS XXXXXX In Subjects with Moderate Hypercholesterolemia (207654)
PI: Jeffrey G. Geohas, MD
178. A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System with XXXXXXXXXXXX for the Episodic Treatment of Recurrent Herpes Labialis (207458)
P: Jeffrey G. Geohas, MD
179. A prospective, multi-center, paired data, cohort screening trial comparing XXXXX to the Fasting Plasma Glucose Test in Subjects at Risk for Diabetes (207793)
PI: Jeffrey G. Geohas, MD
180. A Randomized, Double-Blind, Crossover Study to Compare the Effects of XXXXX and XXXXX on Postprandial Glucose in subjects with Type 2 Diabetes Mellitus (207962)
PI: Jeffrey G. Geohas, MD
181. A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Type 2 Diabetes Mellitus Who Have a Haptoglobin Type 2-2 Genotype and a History of Coronary Artery Disease (204908)
PI: Jeffrey G. Geohas, MD
182. A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of XXXXXX: 26-week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks) – and XXXX (26 Weeks)- Controlled, Multicenter Study XXXXXX (375 mg bid and 750 mg bid) with a 26-Week XXXXX-Controlled Safety Follow-up in Subjects with Osteoarthritis of the Knee, and a 1-Week Post-treatment Safety Follow-up (207868)
PI: Jeffrey G. Geohas, MD
183. A Phase IV Clinical Trials to Evaluate the Safety and Tolerability of XXXXXX in Subjects \geq 60 Years of Age (208080)
PI: Jeffrey G. Geohas, MD
184. A Phase 2 12 Week, Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study Evaluating the Efficacy, Tolerability and Safety of XXXXXXXXXXXX Succinate For Stress Urinary Incontinence in Women (207911)
PI: Jeffrey G. Geohas, MD
185. A Phase 2, 12 Week, Multi-Center, Randomized Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study Evaluating The Efficacy, Safety and Tolerability of XXXXXXXXXXXX Succinate For Urge Urinary Incontinence in Women (207912)
PI: Jeffrey G. Geohas, MD
186. A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800 or 1600 mg/day of XXXXXX Administered Orally Once Daily with a Reduced Calorie Diet in Obese Males and Females (207869)
PI: Jeffrey G. Geohas, MD

187. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXXXXXXX in Adult Subjects with Type 2 Diabetes Mellitus (207021)
PI: Jeffrey G. Geohas, MD
188. A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of XXXXXXXX Capsules and Placebo in the Treatment of Onychomycosis of the Toenail (207252)
PI: Jeffrey G. Geohas, MD
189. A Randomized, Double-Blind, Multiple-Site, Placebo-controlled Study comparing XXXXXX to XXXXXX in the Treatment of Acne Vulgaris. (208058)
PI: Jeffrey G. Geohas, MD
190. A Multi-Center, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of XXXXXX Combination Tablet compared to XXXXXX + XXXXXX in Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia (207945)
PI: Jeffrey G. Geohas, MD
191. Efficacy And Safety Of XXXXXXXX In The Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive To PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study (208163)
PI: Jeffrey G. Geohas, MD
192. A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects with Dyslipidemia (207840)
PI: Jeffrey G. Geohas, MD
193. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A XXXXXXXXX Flexible Dose Regimen in Patients With Overactive Bladder (208148)
PI: Jeffrey G. Geohas, MD
194. Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and lot Consistency of XXXXXXXX Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 (206909)
PI: Jeffrey G. Geohas, MD
195. Immunogenicity and Safety of two dosages of the split, inactivated, trivalent XXXXXX XXXXXX administered by Intradermal Route in the Elderly Compared with Standard XXXXXX in Adults and Elderly Subjects (208154)
PI: Jeffrey G. Geohas, MD
196. A Prospective, multi-center, paired data, cohort screening trial comparing XXXXXXXX to the Fasting Plasma Glucose Test in Subjects at risk for diabetes (208120)
P: Jeffrey G. Geohas, MD
197. A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/day of XXXXXXXX Administered Orally Once Daily with an Initial 6-Week low Calorie Diet in Obese Males and Females (208135)
PI: Jeffrey G. Geohas, MD
198. Immunogenicity of two Dosages of a Split, Cell-Based, Inactivated, Trivalent XXXXXXXX Produced in the PER.C6 Line, Administered in Healthy Adult Subjects Aged 18 to 49 Years (208156)
PI: Jeffrey G. Geohas, MD
199. Phase 3 Double Blind Clinical Study Comparing The Effectiveness and Safety of XXXXXXXXX With XXXXXXXX In The Prevention Of XXXXXXXX like Illness (208302)
PI: Jeffrey G. Geohas, MD
200. Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational XXXXXXXX to Prevent Culture Confirmed XXXXX (208394)
PI: Jeffrey G. Geohas, MD
201. Double-Blind, Parallel-Group Comparision of 23 mg XXXXXXXX Sustained Release to 10 mg XXXXXXXX Immediate Release in Patients with Moderate to Severe Alzheimer's Disease (207634)
PI: Jeffrey G. Geohas, MD
202. A Double-blind, Randomized, Controlled Trial to Assess the Influence of Consuming XXXXXXXX on Fasting Lipids in Men and Women with Primary Hypercholesterolemia (208278)
PI: Jeffrey G. Geohas, MD
203. A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of XXXXXX as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in XXXX subjects with mild to moderate Alzheimer's disease. (207044)
PI: Jeffrey G. Geohas, MD
204. A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effects Of XXXX on Cognitive Functions In The Elderly (207401)
PI: Jeffrey G. Geohas, MD
205. A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of XXXXXX in Subjects 50 to 59 Years of Age (208233)
PI: Jeffrey G. Geohas, MD

206. Open Label Study of the Effect of Daily Treatment with XXXXX in Subjects with Dementia of the Alzheimer's Type. (207258)
PI: Jeffrey G. Geohas, MD
207. Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXXXXXX on Measures of Cognition, Activities of Daily Living, and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (207226)
PI: Jeffrey G. Geohas, MD
208. Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (204649)
PI: Jeffrey G. Geohas, MD
209. A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from XXXX to an initial dose of XXXXXXXX Formulation in Patients with Probable Alzheimer's Disease (207773)
PI: Jeffrey G. Geohas, MD
210. A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of XXXXX Sustained Release XXXXXXX Sustained Release and Placebo in Obese Subjects (207470)
PI: Jeffrey G. Geohas, MD
211. A Multi-Site, Cross-Sectional, Non-Treatment, Prospective Trial to Collect XXXXX and XXXXXXXX data from cognitively normal elderly subjects. (207373)
PI: Jeffrey G. Geohas, MD
212. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of XXXXXXXX Compared to Open-Label Atrovastatin in Patients with Hypercholesterolemia (208232)
PI: Jeffrey G. Geohas, MD
213. "A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of XXXX in patients with mild-to-moderate dementia of the Alzheimer's type" (207293)
PI: Jeffrey G. Geohas, MD
214. A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter study to Determine the Safety and Efficacy of XXXXX on the Treatment of Obesity in Adults with Obesity-Related Co-Morbid Conditions (208380)
PI: Jeffrey G. Geohas, MD
215. A Long-Term Safety and Efficacy Study of XXXXXXX in Elderly Subjects With Primary Chronic Insomnia. (207277)
PI: Jeffrey G. Geohas, MD
216. Assessment of the Content Validity of the Flushing Assessment Tool (FAST) (208407)
PI: Jeffrey G. Geohas, MD
217. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination of XXXXXXXX (Formerly BMS 201038) and XXXXX 20mg vs XXXXXXXX in Subjects with Moderate Hypercholesterolemia (208477)
PI: Jeffrey G. Geohas, MD
218. A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXXXXXX 50mg or Placebo When Coadministered With Statins in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension (208173)
PI: Jeffrey G. Geohas, MD
219. A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXXX in Overweight and obese Patients (208448)
PI: Jeffrey G. Geohas, MD
220. A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study with a Double Blind Extension Investigating the Efficacy and Safety of a Fast-Dissolving XXXXX Formulation of XXXXXXXX for the Treatment of Nocturia in Adults (207584)
PI: Jeffrey G. Geohas, MD
221. A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving XXXXXXXX Formulation of XXXXXXXX for the Treatment of Nocturia in Adults (208519)
PI: Jeffrey G. Geohas, MD
222. A phase IIb, multi-center, randomized, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of XXXXX in Subjects with Premature Ejaculation (PE) (208168)
PI: Jeffrey G. Geohas, MD
223. A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of XXXXXXXX on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System in an "At-Home Setting" in an Adult Population with Chronic Insomnia (207469)
PI: Jeffrey G. Geohas, MD
224. A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of XXXXXXXX in Subjects with Dyslipidemia. (208912)
PI: Jeffrey G. Geohas, MD

225. A 12-Week, Phase 2A, Randomized, Subject and Investigator Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of XXXXXXXXXX on Glucose Control and Body Weight in Overweight Adult Subjects with Type 2 Diabetes Mellitus (208468)
PI: Jeffrey G. Geohas, MD
226. Evaluation of XXXXXXXXXX on Carotid Intima-Media Thickness in Subjects with Type IIa and IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial (208547)
PI: Jeffrey G. Geohas, MD
227. A Phase 3, Observer-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and immunogenicity of a two-dose series of XXXXXX XXXXXXXX antigen in association with XXXX adjuvant in adults aged ≥ 18 years (208555)
PI: Jeffrey G. Geohas, MD
228. Open-Label Extension Study of 23 mg XXXXXXXX in Patients with Moderate to Severe Alzheimer's Disease (208568)
PI: Jeffrey G. Geohas, MD
229. A Prospective, multi-center, paired data, cohort screening trial comparing XXXXXXXX to the Fasting Plasma Glucose Test in Subjects at risk for diabetes (208528)
PI: Jeffrey G. Geohas, MD
230. A Phase 2, 240Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate The Effect of XXXXXXXXXXXXXXXX on Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density (208603)
PI: Jeffrey G. Geohas, MD
231. 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate The Efficacy and Safety Of XXXXXXXX In Comparison To Tolterodine ER in Patients With overactive Bladder (208627)
PI: Jeffrey G. Geohas, MD
232. A Post Hoc Study to Evaluate the Baseline Surrogate Biomarkers of Oxidative Stress and Inflammation in Subjects with Type 2 Diabetes Mellitus Who Have a Haptoglobin Type 1-1 Genotype and a History of Coronary Artery Disease (208752)
PI: Jeffrey G. Geohas, MD
233. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXXXXX Administered in Conjunction with XXXX in Obese and Overweight Subjects (208690)
PI: Jeffrey G. Geohas, MD
234. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) XXXXXXXX When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients (208920)
PI: Jeffrey G. Geohas, MD
235. A Randomized, Open-Label, Parallel-Group, Multicenter Study to Evaluate the Comparability of the Glycemic Effects of XXXXXXXX once weekly from two different manufacturing sites in subjects with Type 2 Diabetes Mellitus (208979)
PI: Jeffrey G. Geohas, MD
236. 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of XXXXXXXX in Comparison to Tolterodine ER in Patients with Overactive Bladder (208627)
PI: Jeffrey G. Geohas, MD
237. A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of XXXXXXXX plus XXXXXXXX Combination Therapy in Subjects with Uncomplicated Obesity (208698)
PI: Jeffrey G. Geohas, MD
238. A Phase I, Randomized, Observer-blind, Multicenter, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted XXXX Submit Influenza Virus Vaccine in Healthy Subjects 18 – 40 Years of Age (207889)
PI: Jeffrey G. Geohas, MD
239. A Phase 2, Observer-blind, Randomized, Multi-Center Trial to Evaluate the Safety and Immunogenicity of Heterologous Booster Vaccination with XXXXXXXXXXXX Vaccine Adjuvanted with XXXX given 6 or 12 Months following a single priming dose of XXXXXXXXXXXX Vaccine Antigen Adjuvanted with AS03 in Adults 18 years of age or older (208782)
PI: Jeffrey G. Geohas, MD
240. Open-Label Extension (OLE) Safety and Efficacy Study of XXXXXXXX following The Year-Long Controlled Clinical Trials of XXXXXXXX in Obese Males and Females (209141)
PI: Jeffrey G. Geohas, MD
241. Lot Consistency, Immunogenicity, and Safety Study of Three Lots of XXXXXXXX Vaccine Administered by Intradermal Route in Comparison with Standard XXXXXXXX® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years (208868)
PI: Jeffrey G. Geohas, MD
242. Safety and Immunogenicity of Revaccination with XXXXXXXX in Ambulatory Elderly Subjects Previously Vaccinated with XXXX IM (208869)
PI: Jeffrey G. Geohas, MD
243. Extension Study of Protocol DFA102 To Examine The Long-Term Safety, Tolerability, And Effect On Body Weight Of XXXXXXXXXXXX Administered in Combination with XXXXXXXX in Obese And Overweight Subjects (209366)
PI: Jeffrey G. Geohas, MD

244. Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal XXXXXXXXXX in Adults 50 Years of Age and Older (209345)
PI: Jeffrey G. Geohas,
245. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Subcutaneous AC2307 in Obese or overweight subjects (209414)
PI: Jeffrey G. Geohas, MD
246. Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived XXXXXXXX to Prevent Culture Confirmed XXXXXXXX Infection (209384)
PI: Jeffrey G. Geohas, MD
247. A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of XXXXXXXXXX 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia (209518)
PI: Jeffrey G. Geohas, MD
248. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Different Doses of XXXXXXX in Combination With a Statin vs. Statin Mono-Therapy in Patients With Hyperlipidemia (209496)
PI: Jeffrey G. Geohas, MD
249. A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study Evaluating the Efficacy, Safety and Tolerability of XXXXXXX Administered Twice Daily for 24 Weeks in Treatment-naïve, Metformin Only or Metformin plus Sulfonylurea-treated Obese Type 2 Diabetic Patients (PROMOTE) (209826)
PI: Jeffrey G. Geohas, MD
250. Safety and Immunogenicity of Revaccination with Influenza Vaccine in Healthy Adult Subjects aged 18 to 64 Years who were Previously Vaccinated with XXXXXXXXXX or XXXXXXXXXX (209743)
PI: Jeffrey G. Geohas, MD
251. A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273 in adults aged 18 years and older (209964)
PI: Jeffrey G. Geohas, MD
252. An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of XXXXXXXX to Licensed Vaccine (Engerix-B) among Healthy Subjects 40 to 70 Years of Age (210037)
PI: Jeffrey G. Geohas, MD
253. A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXXX in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with their Lipid Modifying Therapy
PI: Jeffrey G Geohas, MD
254. A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of XXXX in Patients with Type 2 Diabetes Mellitus
PI: Jeffrey G Geohas, MD
255. PDT-01-Safety and Efficacy of XXXX in Patients with Hyperlipidemias: A Pilot Study
PI: Jeffrey G Geohas, MD
256. Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of XXXXXXXX in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder
Co-investigator: Jeffrey G Geohas, MD
257. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Effects of XXXXXXX on Women with Recent History of Urinary Tract Infections
PI: Jeffrey G Geohas, MD
258. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXXX in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
PI: Jeffrey G Geohas, MD
259. A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and tolerability of XXX once Weekly Suspension to XXXXX and Placebo in Subjects with Type 2 Diabetes Mellitus
PI: Jeffrey G Geohas, MD
260. A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of XXXXX to that of XXX XXX once daily and XXX three times daily in patients with Type 2 diabetes insufficiently controlled with XXX XXX with or without metformin
PI: Jeffrey G Geohas, MD
261. An Efficacy and Safety Study of XXXX in Adults with Hypertriglyceridemia
PI: Jeffrey G Geohas, MD

262. A Double-blind, Randomized, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of XXXXX for 12 Weeks Followed by a 4-week Withdrawal Period
PI: Jeffrey G Geohas, MD
263. A Multicenter, Open-label, Safety and Tolerability Extension Trial of XXXXX Daily in the Treatment of Chronic Idiopathic Constipation
PI: Jeffrey G Geohas, MD
264. A Randomized, Double-Blind, (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, Compared With Placebo and XXXX (XXXX, Open-Label) as an Active Control
PI: Jeffrey G Geohas, MD
265. A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, With XXXXX as an Active Control
PI: Jeffrey G Geohas, MD
266. A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral XXXXX Compared With XXXXXX When Used in Combination With Metformin in Subjects With Type 2 Diabetes
PI: Jeffrey G Geohas, MD
267. A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXX mg Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
PI: Jeffrey G Geohas, MD
268. A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of XXXX Peptide Immunotherapy in Cat Allergic Subjects
Co-Investigator: Jeffrey G Geohas, MD
269. A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12 Week Phas II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXXX Once Daily Versus Placebo in Statin Stable Subjects with Mixed Dyslipidemia
PI: Jeffrey G Geohas, MD
270. A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with XXXX or XXXX
PI: Jeffrey G Geohas, MD
271. A 20-week, double-blind, randomized, placebo-controlled, parallel-group trial to assess the safety and efficacy of XXXX on body weight in obese subjects without diabetes
PI: Jeffrey G Geohas, MD
272. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of XXXXX In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
PI: Jeffrey G Geohas, MD
273. Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, and Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
PI: Jeffrey G Geohas, MD
274. Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk
PI: Jeffrey G Geohas, MD
275. A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of XXXXXX twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus
PI: Jeffrey G Geohas, MD
276. A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomized, multicentre trial to assess effect on glycaemic control of three doses of XXXXX in subjects with inadequately controlled type 2 diabetes receiving a stable dose of metformin
PI: Jeffrey G Geohas, MD
277. Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732, & LTX11717 Studies to Assess the Long-Term Safety and Efficacy of XXXXX in Patients with Heterozygous Familial Hypercholesterolemia
PI: Jeffrey G Geohas, MD
278. A 26 week, randomized, active-controlled safety study of double-blind XXXXX XXXXX in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma
PI: Jeffrey G Geohas, MD
279. A randomized, open-label, active-controlled, parallel-group, multicenter, long-term safety trial of treatment with nebulized XXXX in patients with COPD: Golden-5 (XXX for Obstructive Lung Disease via electronic nebulizer)
PI: Jeffrey G Geohas, MD
280. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2A Study with an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily XXXX in Type 2 Diabetic Patients Inadequately Controlled with Metformin
PI: Jeffrey G Geohas, MD

281. An Efficacy and Safety Study of Sustained-release XXXXXXX in Subjects with Osteoarthritis
PI: Jeffrey G Geohas, MD